[{"id":"4ca8b414-9077-4b6b-b132-a2fdb98fe759","acronym":"","url":"https://clinicaltrials.gov/study/NCT04521946","created_at":"2021-01-18T21:39:42.879Z","updated_at":"2024-07-02T16:35:34.835Z","phase":"Phase 1","brief_title":"Chemotherapy and Donor Stem Transplant for the Treatment of Patients With High Grade Brain Cancer","source_id_and_acronym":"NCT04521946","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" HLA-DRB1 • HLA-B • HLA-C • KIR2DS2","pipe":"","alterations":" ","tags":["HLA-DRB1 • HLA-B • HLA-C • KIR2DS2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e etoposide IV • melphalan • fludarabine IV • thiotepa"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 01/14/2021","start_date":" 01/14/2021","primary_txt":" Primary completion: 12/20/2022","primary_completion_date":" 12/20/2022","study_txt":" Completion: 12/20/2022","study_completion_date":" 12/20/2022","last_update_posted":"2023-10-04"},{"id":"7f86cc3f-f36b-43ca-a75f-ceecaeea4f8b","acronym":"","url":"https://clinicaltrials.gov/study/NCT01787474","created_at":"2022-07-13T07:55:08.172Z","updated_at":"2024-07-02T16:36:28.828Z","phase":"Phase 1/2","brief_title":"Donor Natural Killer Cells in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia","source_id_and_acronym":"NCT01787474","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" KIR2DS2","pipe":"","alterations":" ","tags":["KIR2DS2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cytarabine • fludarabine IV • Neupogen (filgrastim) • Starasid (cytarabine ocfosfate)"],"overall_status":"Completed","enrollment":" Enrollment 30","initiation":"Initiation: 05/19/2014","start_date":" 05/19/2014","primary_txt":" Primary completion: 06/17/2021","primary_completion_date":" 06/17/2021","study_txt":" Completion: 06/17/2021","study_completion_date":" 06/17/2021","last_update_posted":"2021-06-21"},{"id":"c16de0cf-b9fe-4442-8cd2-246fe6771da8","acronym":"","url":"https://clinicaltrials.gov/study/NCT01287104","created_at":"2021-01-18T05:13:27.987Z","updated_at":"2024-07-02T16:36:56.638Z","phase":"Phase 1","brief_title":"A Phase I Study of NK Cell Infusion Following Allogeneic Peripheral Blood Stem Cell Transplantation From Related or Matched Unrelated Donors in Pediatric Patients With Solid Tumors and Leukemias","source_id_and_acronym":"NCT01287104","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" FLT3 • NPM1 • CEBPA • CD4 • IL15 • IL7 • KIR2DS2","pipe":" | ","alterations":" FLT3-ITD mutation • NPM1 mutation • CEBPA mutation • Chr del(5q)","tags":["FLT3 • NPM1 • CEBPA • CD4 • IL15 • IL7 • KIR2DS2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FLT3-ITD mutation • NPM1 mutation • CEBPA mutation • Chr del(5q)"],"overall_status":"Completed","enrollment":" Enrollment 34","initiation":"Initiation: 01/29/2011","start_date":" 01/29/2011","primary_txt":" Primary completion: 06/28/2018","primary_completion_date":" 06/28/2018","study_txt":" Completion: 06/28/2018","study_completion_date":" 06/28/2018","last_update_posted":"2019-08-22"}]